Advancements in Nanotechnology and Biosensor Integration for Detection and Treatment of Alice in Wonderland Syndrome

Year : 2024 | Volume : 26 | Issue : 03 | Page : 1 12
    By

    S. Anand,

  1. Professor, Department of Computer Science and Engineering, Infant Jesus College of Engineering, Thoothukudi, Tamil Nadu, India

Abstract

Alice in Wonderland Syndrome (AIWS) is an uncommon neurological condition characterized by profound distortions in perception. Individuals with AIWS experience altered body image and spatial awareness, often perceiving objects, surroundings, or even their own body as being unusually large, small, or distorted. The condition presents a unique challenge for both diagnosis and management due to its elusive and varied symptoms. This paper explores how advancements in nanotechnology and biosensor integration can transform the approach to detecting and treating AIWS. Nanotechnology, with its ability to manipulate matter at the molecular level, offers novel solutions for diagnosing and managing neurological disorders. Nanoparticles can be designed to penetrate the blood-brain barrier, allowing for precise delivery of therapeutic or imaging agents. This capability enhances the treatment of neurological disorders and improves the detection of abnormalities within the brain. Similarly, biosensors, which can detect biological signals with high specificity and sensitivity, promise to revolutionize real-time monitoring of AIWS symptoms and neurological activity. By conducting a thorough review of recent literature and experimental research, we emphasize the potential of these emerging technologies in relation to Alice in Wonderland Syndrome (AIWS). Specifically, we explore how nanoparticles could be employed to deliver medications directly to the brain regions impacted by the disorder, thereby reducing side effects and optimizing therapeutic effectiveness. Biosensors could enable continuous monitoring of neurological parameters, allowing for more precise adjustment of treatment strategies and early detection of symptom changes. Our findings indicate that the integration of nanotechnology and biosensors offers unprecedented opportunities for early detection, precise treatment, and enhanced quality of life for individuals with AIWS. By leveraging these advanced technologies, it is possible to move towards more personalized medicine and targeted therapies, ultimately paving the way for significant advancements in the management of neurological disorders. This research underscores the transformative potential of combining these cutting-edge technologies in the quest to understand and address the complexities of AIWS

Keywords: Alice in Wonderland Syndrome, nanotechnology, biosensors, neurological disorders, perception distortion, nanoparticles, drug delivery, symptom management, personalized medicine

[This article belongs to Nano Trends – A Journal of Nano Technology & Its Applications ]

How to cite this article:
S. Anand. Advancements in Nanotechnology and Biosensor Integration for Detection and Treatment of Alice in Wonderland Syndrome. Nano Trends – A Journal of Nano Technology & Its Applications. 2024; 26(03):1-12.
How to cite this URL:
S. Anand. Advancements in Nanotechnology and Biosensor Integration for Detection and Treatment of Alice in Wonderland Syndrome. Nano Trends – A Journal of Nano Technology & Its Applications. 2024; 26(03):1-12. Available from: https://journals.stmjournals.com/nts/article=2024/view=179067


References

  1. Tunç S, Başbuğ HS. Alice in Wonderland syndrome: a strange visual perceptual disturbance. Psychiatry Clin Psychopharmacol. 2017;27(4):412–5.
  2. Mukherjee S, Residence N, Thakur M, Chourasiya V, Saha S, Dube D, et al. Recent advancements of nanomedicine in neurodegenerative disorders theranostics. Adv Funct Mater. 2020;30(35):2003054.
  3. Sudharshan VB. Human like biosensor disease simulator, disease analyzer and drug delivery system. In: 2013 IEEE Conference on Information and Communication Technologies, ICT 2013; 2013. p.1033–8.
  4. Blom JD. Alice in Wonderland syndrome: a systematic review. Neurol Clin Pract. 2016;6(3):259–70.
  5. Yokoyama T, Yamamoto T, Saki N, Masuda T. A case of recurrent depressive disorder presenting with Alice in Wonderland syndrome: psychopathology and pre-and post-treatment FDG-PET findings. BMC Psychiatry. 2017;17:1–6.
  6. Krol S, Wöhrle T, Ehlert J, Möller M. Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier. Chem Rev. 2013;113(3):1877–903.
  7. Ganji MR, Thakur MS. Microprocessor based biosensors for determination of toxins and pathogens in restricted areas of human intervention. In: Proceedings of the International Conference on Artificial Intelligence, IC-AI’04; 2004. p. 525–31.
  8. Campora S, Ghersi G. Recent developments and applications of smart nanoparticles in biomedicine. Nanotechnology Rev. 2022;11(1):2595–631.
  9. Pasqualotto E, Federici S, Olivetti Belardinelli M. Toward functioning and usable brain–computer interfaces (BCIs): A literature review. Disabil Rehabil Assist Technol. 2012;7(2):89–103.
  10. Yin PT, Li Z, Chen W, et al. Design, synthesis, and characterization of graphene-nanoparticle hybrid materials for bioapplications. Chem Rev. 2015;115(7):2483–531.
  11. Eswaran U, Rani A, Venkatesh C, et al. Design and analysis of high sensitive microcantilever-based biosensor for CA 15–3 biomarker detection. J Appl Sci Comput. 2018;5(7):682–98. DOI: 16.10089.JASC.2018.V5I7.453459.0050021.
  12. Jena BK, Raj CR. Electrochemical biosensor based on integrated assembly of dehydrogenase enzymes and gold nanoparticles. Anal Chem. 2006;78(18):6332–9.
  13. Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in vitro testing. Mol Pharm. 2010;7(5):1388–405.
  14. Xu Y, Zhang Y, Yang B, et al. An overview of in vitro, ex vivo and in vivo models for studying the transport of drugs across intestinal barriers. Adv Drug Deliv Rev. 2021;175:113795.
  15. Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr. 2003;133(10):3275S–84S.
  16. Belanger HG, Barlow A, O’Connell K, et al. Recent neuroimaging techniques in mild traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2007;19(1):5–20.
  17. Conway JRW, Carragher NO, Timpson P. Developments in preclinical cancer imaging: innovating the discovery of therapeutics. Nat Rev Cancer. 2014;14(5):314–28.
  18. Stearns LJ, McAbney E, Von Roenn JH, et al. Assessment of health care utilization and cost of targeted drug delivery and conventional medical management vs conventional medical management alone for patients with cancer-related pain. JAMA Netw Open. 2019;2(4):e191549.
  19. Wilson GS, Gifford R. Biosensors for real-time in vivo measurements. Biosens Bioelectron. 2005;20(12):2388–403.
  20. Murali K, Rahiman M, Hwang Y, et al. Application of sensors for smart farming. In: Khang A, editor. Agriculture and aquaculture applications of biosensors and bioelectronics. IGI Global; 2024. p. 18–44. https://doi.org/10.4018/979-8-3693-2069-3.ch002.
Regular Issue Subscription Review Article
Volume 26
Issue 03
Received 19/09/2024
Accepted 26/09/2024
Published 22/10/2024
Publication Time 33 Days
303

Login


My IP

PlumX Metrics